 Connection
Marshall Lucia to Biopsy, Needle
This is a "connection" page, showing publications Marshall Lucia has written about Biopsy, Needle.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.034 |
|
|
|
-
Iczkowski KA, Lucia MS. Current perspectives on Gleason grading of prostate cancer. Curr Urol Rep. 2011 Jun; 12(3):216-22.
Score: 0.351
-
Stone NN, Mouraviev V, Schechter D, Goetz J, Lucia MS, Smith EE, Crawford ED. Deflection Analysis of Different Needle Designs for Prostate Biopsy and Focal Therapy. Technol Cancer Res Treat. 2017 10; 16(5):654-661.
Score: 0.127
-
Werahera PN, Jasion EA, Crawford ED, La Rosa FG, Lucia MS, van Bokhoven A, Sullivan HT, Port JD, Maroni PD, Daily JW. Systematic diagnosis of prostate cancer using an optical biopsy needle adjunct with fluorescence spectroscopy. Annu Int Conf IEEE Eng Med Biol Soc. 2014; 2014:2165-8.
Score: 0.105
-
Lucia MS, Bostwick DG, Somerville MC, Fowler IL, Rittmaster RS. Comparison of Classic and International Society of Urological Pathology 2005 Modified Gleason grading using needle biopsies from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. Arch Pathol Lab Med. 2013 Dec; 137(12):1740-6.
Score: 0.104
-
Lucia MS, Bokhoven Av. Temporal changes in the pathologic assessment of prostate cancer. J Natl Cancer Inst Monogr. 2012 Dec; 2012(45):157-61.
Score: 0.097
-
Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, Tangen CM, Parnes HL, Lippman SM, La Rosa FG, Kattan MW, Crawford ED, Ford LG, Coltman CA, Thompson IM. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007 Sep 19; 99(18):1375-83.
Score: 0.068
-
Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL, Coltman CA. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006 Apr 19; 98(8):529-34.
Score: 0.062
-
Tangen CM, Goodman PJ, Till C, Schenk JM, Lucia MS, Thompson IM. Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical Trials. J Clin Oncol. 2016 12 20; 34(36):4338-4344.
Score: 0.032
-
Troyer DA, Lucia MS, de Bru?ne AP, Mendez-Meza R, Baldewijns MM, Dunscomb N, Van Engeland M, McAskill T, Bierau K, Louwagie J, Bigley JW. Prostate cancer detected by methylated gene markers in histopathologically cancer-negative tissues from men with subsequent positive biopsies. Cancer Epidemiol Biomarkers Prev. 2009 Oct; 18(10):2717-22.
Score: 0.019
-
Thompson IM, Tangen CM, Ankerst DP, Chi C, Lucia MS, Goodman P, Parnes H, Coltman CA. The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy. J Urol. 2008 Aug; 180(2):544-7.
Score: 0.018
-
Bansal S, Lucia MS, Wiseman A. A case of polyomavirus-associated nephropathy presenting late after transplantation. Nat Clin Pract Nephrol. 2008 May; 4(5):283-7.
Score: 0.018
-
Thompson IM, Pauler Ankerst D, Chi C, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. J Clin Oncol. 2007 Jul 20; 25(21):3076-81.
Score: 0.017
-
Weiss AS, Lucia MS, Teitelbaum I. A case of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis. Nat Clin Pract Nephrol. 2007 Feb; 3(2):111-5.
Score: 0.016
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|